LUND, Sweden – May 12, 2026
BioInvent International AB announced that new clinical findings from its ongoing Phase 1/2 study evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. The presentation will showcase emerging efficacy, safety, and mechanistic data supporting the potential of BI-1206 to overcome resistance to CD20-targeted therapies in difficult-to-treat B-cell lymphomas. BioInvent stated that the investigational FcγRIIB antibody is designed to block one of the key resistance mechanisms limiting the effectiveness of rituximab, while simultaneously enhancing anti-tumor activity when combined with BTK inhibition through acalabrutinib. The latest findings further strengthen BioInvent’s position within the rapidly expanding field of next-generation immuno-oncology combination therapies for hematologic malignancies.
BI-1206 Combination Shows Strong Activity in Resistant NHL
According to BioInvent, the ongoing study is evaluating the triplet combination of subcutaneous BI-1206, rituximab, and acalabrutinib in patients with indolent B-cell non-Hodgkin’s lymphoma who relapsed after or became refractory to rituximab-based treatment. The study includes patients across multiple countries including Spain, Germany, the United States, and Brazil, with enrollment of approximately 30 patients now completed. Researchers believe the combination strategy addresses a major limitation associated with long-term CD20-targeted therapy by directly blocking FcγRIIB (CD32B)-mediated rituximab internalization, a known biological pathway contributing to therapeutic resistance and poor clinical outcomes in aggressive and recurrent lymphoma cases.
Previously presented data at the 2025 American Society of Hematology (ASH) meeting demonstrated highly encouraging anti-tumor activity for the triplet regimen. Among 15 evaluable patients in the safety run-in cohort, the combination achieved an 80% objective response rate (ORR), including seven complete responses (CRs) and five partial responses (PRs), alongside a 100% disease control rate (DCR). BioInvent also reported that the majority of patients remained on treatment at the data cutoff, suggesting durable clinical benefit. Updated analyses from February 2026 involving 20 evaluable patients continued to show sustained response levels, maintaining both the 80% ORR and 100% DCR observed earlier in development.
The company emphasized that treatment tolerability has remained favorable throughout the study, with approximately 87% of treatment-related adverse events classified as mild or moderate in severity. These findings are considered important because patients with relapsed or refractory NHL often have limited treatment options and may experience cumulative toxicities following multiple prior lines of therapy. The combination’s balance between efficacy and manageable safety may position BI-1206 as a potentially differentiated therapy within the increasingly competitive B-cell malignancy treatment landscape.
FcγRIIB Targeting Offers Novel Resistance-Reversal Strategy
Advertisement
BioInvent stated that BI-1206 works through a differentiated mechanism specifically designed to restore and enhance the effectiveness of rituximab-based therapy. FcγRIIB is highly overexpressed in several forms of non-Hodgkin’s lymphoma and has been associated with poor prognosis, particularly in aggressive subtypes such as mantle cell lymphoma. By blocking FcγRIIB on tumor cells, BI-1206 prevents internalization and removal of rituximab from the cancer cell surface, thereby preserving CD20 targeting and improving anti-tumor immune responses.
The addition of acalabrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, further strengthens the therapeutic strategy by disrupting B-cell signaling pathways critical for lymphoma cell survival and proliferation. Researchers believe combining FcγRIIB blockade with BTK inhibition may create synergistic anti-cancer activity capable of improving responses in rituximab-resistant disease. The study is being conducted under a clinical supply agreement with AstraZeneca, which provides Calquence® (acalabrutinib) for the trial.
Industry analysts consider resistance-reversal strategies an increasingly important focus area in hematologic oncology, particularly as long-term use of monoclonal antibodies and targeted therapies leads to more treatment-refractory patient populations. The strong early efficacy signals observed with BI-1206 suggest FcγRIIB blockade may represent a novel immunotherapeutic approach capable of extending the clinical utility of established CD20-targeted regimens in NHL and potentially other B-cell malignancies.
BioInvent Expands Immuno-Oncology Development Pipeline
The EHA2026 presentation reflects BioInvent’s broader effort to build a diversified pipeline of first-in-class immune-modulatory antibodies targeting both hematologic cancers and solid tumors. In addition to BI-1206, the company is advancing several immunotherapy programs including BI-1808, an anti-TNFR2 antibody currently being evaluated in T-cell lymphomas and solid tumors. BioInvent’s proprietary F.I.R.S.T™ platform is designed to identify novel immune targets and therapeutic antibodies capable of reshaping tumor immune responses and overcoming resistance mechanisms across oncology indications.
The company generates additional revenue through licensing agreements, research collaborations, and antibody manufacturing partnerships with multiple global pharmaceutical organizations. BioInvent executives stated that the latest EHA2026 findings reinforce the company’s strategy of combining novel immune-modulatory antibodies with established oncology therapies to improve outcomes for patients with relapsed and treatment-resistant cancers.
As immuno-oncology continues evolving toward increasingly personalized and mechanism-driven combination strategies, BioInvent aims to position BI-1206 among the emerging next-generation antibody therapies designed to overcome resistance and restore durable anti-cancer responses in hematologic malignancies.
Source: BioInvent press release
